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Abstract: Diabetic kidney disease is the most frequent cause of end-stage renal disease. 
This implies failure of current therapeutic approaches based on renin-angiotensin system 
(RAS) blockade. Recent phase 3 clinical trials of paricalcitol in early diabetic kidney 
disease and bardoxolone methyl in advanced diabetic kidney disease failed to meet the 
primary endpoint or terminated on safety concerns, respectively. However, various novel 
strategies are undergoing phase 2 and 3 randomized controlled trials targeting 
inflammation, fibrosis and signaling pathways. Among agents currently undergoing trials 
that may modify the clinical practice on top of RAS blockade in a 5-year horizon,  
anti-inflammatory agents currently hold the most promise while anti-fibrotic agents have 
so far disappointed. Pentoxifylline, an anti-inflammatory agent already in clinical use, was 
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recently reported to delay estimated glomerular filtration rate (eGFR) loss in chronic 
kidney disease (CKD) stage 3–4 diabetic kidney disease when associated with RAS 
blockade and promising phase 2 data are available for the pentoxifylline derivative  
CTP-499. Among agents targeting chemokines or chemokine receptors, the oral small 
molecule C-C chemokine receptor type 2 (CCR2) inhibitor CCX140 decreased 
albuminuria and eGFR loss in phase 2 trials. A dose-finding trial of the anti-IL-1β antibody 
gevokizumab in diabetic kidney disease will start in 2015. However, clinical development 
is most advanced for the endothelin receptor A blocker atrasentan, which is undergoing a 
phase 3 trial with a primary outcome of preserving eGFR. The potential for success of 
these approaches and other pipeline agents is discussed in detail. 
Keywords: chronic kidney disease; diabetes; diabetic kidney disease; inflammation; 
interleukin-1-beta; treatment 
 
1. Introduction 
The incidence and prevalence of diabetes mellitus (DM) is increasing worldwide due to evolving 
lifestyles and lower mortality from transmissible disease that is prolonging survival and increasing 
global aging [1]. There is a global trend towards a decrease in overall age-standardized mortality. 
Causes of death not following this trend deserve special attention [1]. In terms of ranking for years of 
life lost, chronic kidney disease (CKD) is the non-communicable cause of premature death that 
increased the most over the 1990–2013 period (90% increase), followed by diabetes (67% increase), 
according to the Global Burden of Disease 2013 study [1]. Both were among the top 25 causes of 
death, Much of the mortality due to CKD corresponded to diabetic kidney disease (DKD). Indeed, the 
age-standardized death rate from DKD increased by 106% in this period [1]. These data imply that the 
current approach to prevent and treat DKD, based on renin-angiotensin system (RAS) blockade and 
metabolic and blood pressure control should be further optimized to slow the growing epidemic [2,3]. 
Thus, a number of basic, translational and clinical research initiatives are aiming at improving the 
success rate of DKD therapy. Any new therapy should be more effective than angiotensin converting 
enzyme (ACE) inhibitors or angiotensin type 1 receptor blockers (ARBs) in preventing loss of renal 
function in head-to-head comparisons or improve outcomes when used in addition to RAS blockade. In 
this regard, the widespread use of RAS blockade may underlie the observation that while DKD is still 
the most frequent cause of incident end-stage renal disease (ESRD) (almost 50% according to 2014 
United States Renal Data System (USRDS) data) [4], and among persons with diabetes, the prevalence 
of DKD remained stable (thus exposing patients with increased risk associated with CKD) [5]; it is 
also true that the number of incident cases has stabilized in recent years and the incidence rate has 
started a slow decrease and this may be related to wider implementation of nephroprotective strategies [6]. 
Ethics considerations limit the possibilities regarding head-to-head comparisons. Thus, most agents in 
the pipeline are being tested as add-on agents on top of RAS blockade. This is a rapidly evolving field, 
where some drugs are dismissed following early clinical trials, while new candidates appear in the 
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horizon [7]. We now review the most likely candidates to be in the market by 2020, based on currently 
ongoing or recently completed clinical trials (Tables 1 and 2 and Figure 1). 
 
Figure 1. Promising therapeutic approaches to diabetic kidney disease (DKD) undergoing 
clinical trials. Only drugs and targets under active clinical investigation are shown. Renin 
angiotensin system (RAS) targeting drugs not shown as they are already in clinical use. 
MR: mineralocorticoid receptor. ETA: Endothelin receptor A. 
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Table 1. Therapeutic approaches to diabetic kidney disease (DKD) undergoing clinical trials with primary endpoint albuminuria or glomerular 
filtration rate. Most advanced clinical development phase is reflected [8]. 
Target Drug ClinicalTrials.gov Identifier Phase 
Enrollment 
(Expected) 
Status 
Completed Date 
(or Expectation) 
Vitamin D receptor agonist 
Paricalcitol 
VITAL NCT00421733 II 281 Completed June 2009 
PROCEED NCT01393808 II 112 Ongoing June 2015 
Cholecalciferol NCT00552409  II and III 22 Completed June 2010 
Calcitriol NCT01673204  IV 276 Ongoing April 2014 
Endothelin receptor antagonists 
Avosentan NCT00120328 III 2364 Terminated * February 2007 
Atrasentan 
NCT00920764 II 92 Completed May 2010 
RADAR NCT01356849 II 149 Completed August 2012 
SONAR NCT 01858532 III 4148 Ongoing February 2017 
Mineralocorticoid receptor blockers 
Spironolactone 
NCT00317954 IV 48 Completed July 2005 
PRIORITY NCT02040441 II and III 3500 Ongoing December 2017 
Eplerenone NCT00315016 II 30 Completed July 2011 
MT-3995 NCT01756703 II 67 Completed August 2014 
BAY 94-8862 (Finerenone) NCT01874431 II 821 Completed August 2014 
Cs3150 NCT02345057 II 325 Ongoing July 2016 
Xanthine oxidase Inhibitor 
Topiroxostat NCT02327754 II 60 Ongoing December 2016 
Allopurinol PERL NCT02017171 III 480 Ongoing December 2018 
Phosphodiesterase inhibitor 
Pentoxifylline NCT00663949 II and III 70 Completed January 2008 
PF0489791 NCT01200394 II 256 Completed August 2013 
CTP499 NCT01487109 II 170 Completed January 2015 
Serotonin receptor antagonists Sarpogrelate SONATA NCT01869881 IV 166 Ongoing December 2014 
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Table 1. Cont. 
Target Drug ClinicalTrials.gov Identifier Phase 
Enrollment 
(Expected) 
Status 
Completed Date 
(or Expectation) 
Nuclear factor erythroid 2-related factor 2 
(Nrf2) activators 
Bardoxolone RTA-402 
NCT00811889 II 227 Completed December 2010 
BEACON NCT00664027 III 2185 Terminated ** October 2012 
NCT02316821 II 72 Ongoing December 2017 
Chemokine inhibitors 
PF-04634817 NCT01712061 II 226 Completed September 2014 
CCX 140-B NCT01447147 II 332 Completed December 2014 
BMS-813160 NCT01752985 II 120 Ongoing December 2015 
NFκB inhibitors Bindarit NCT01109212 II 100 Completed December 2008 
Jakinibs Baricitinib NCT01683409 II 129 Completed November 2014 
Antioxidants 
N-Acetylcysteine 
NCT00556465 II and III 69 Completed June 2007 
NCT00915200 II 225 Ongoing March 2015 
NOX-E36 NCT01547897 II 76 Completed December 2013 
Probucol NCT01726816 II 126 Completed September 2014 
Glutathione NCT01265563  II 110 Ongoing February 2015 
GKT137831 NCT02010242 II 200 Completed March 2015 
Colchicine NCT02035891 I, II, III and IV 160 Ongoing June 2018 
Galectin-3 antagonist GCS-100 NCT02312050 II 375 Ongoing Sep 2016 
Integrin blocker VPI-2690B NCT02251067 II 300 Ongoing August 2017 
Apoptosis signal-regulating kinase 1 GS-4997 NCT02177786 II 300 Ongoing August 2016 
Antifibrotic therapies  
Pirfenidone NCT00063583 I and II 77 Completed March 2009 
LY2382770 Anti-TGF-β1 mAb NCT01113801 II 400 Completed *** July 2014 
RAGE inhibitor TTP488 NCT00287183 II 110 Completed August 2009 
Glycosaminoglycans Sulodexide 
NCT00130208 III 1000 Completed February 2008 
NCT00130312 IV 1248 Terminated **** March 2008 
Soften NCT01316068 IV 80 Ongoing August 2012 
Metalloproteinase inhibitor XL784 NCT00312780 II 125 Completed December 2007 
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Table 1. Cont. 
Target Drug ClinicalTrials.gov Identifier Phase 
Enrollment 
(Expected) 
Status 
Completed Date 
(or Expectation) 
Inhibitors of epidermal growth factor ligands TGF-α/epiregulin inhibitor LY3016859 NCT01774981 I and II 64 Ongoing September 2015 
ACTH receptor ACTH  
ACTH-NRDN NCT01028287 IV 15 Completed July 2011 
NCT01601236 II 40 Ongoing January 2015 
DPP-4 Inhibitor Linagliptin 
NCT02376075 III 43 Completed September 2014 
RENALIS NCT02106104 IV 48 Ongoing May 2016 
PKCβ inhibition LY333531 (Ruboxistaurin) NCT00044148 II Not Provided Completed Not Provided 
Inhibitors of AGE formation Pyridoxamine 
NCT00734253 II 317 Completed August 2010 
PIONEER NCT02156843 III 600 Ongoing December 2017 
* Side effect safety concerns related to heart failure probably as a consequence of fluid retention; ** Independent Data Monitoring Committee recommendation for safety 
concerns; *** Although clinicaltrials.gov states “completed”, it was “terminated” for futility; **** No difference in protein excretion at 6 and 12 months. No safety issues; 
mAb, monoclonal antibody. 
Table 2. Recently completed (from 2009) clinical trials enrolling >50 patients with results available. 
Drug Comparator Months N Study Population Primary Endpoint Results 
Paricalcitol  
Placebo vs.(low and 
high dose of drug) 
6 281 
T2DM, on RAS blockade. GFR: 
15–90. UACR: 100–3000 
UACR 
Low dose group: −14%, High dose group: 
−20, Placebo group: −3%. Drug versus 
placebo −15% (p = 0.071) 
Atrasentan 
Placebo (vs. 3 doses 
of the drug) 
2 89 
T2DM, on RAS blockade. GFR: 
>20 UACR: 100–3000 
UACR 
Reduction by 35%–42% versus 11% for 
placebo (p < 0.005)  
Placebo (vs. 2 doses 
of the drug) 
3 211 
T2DM, on RAS blockade. GFR: 
30–75 UACR: 300–3500 
UACR Reduction by 35%–38%  
BAY 94-8862 
(Finerenone) 
Placebo (vs. 7 doses 
of the drug) 
3 821 
T2DM, on RAS blockade. GFR: 
30–90 UACR: 30–300 and  
300–3000 
UACR 
Dose-dependently reduced UACR. Mean ratio 
of UACR in the two highest doses vs. placebo 
was 0.62 and 0.67 (p < 0.0001 either) 
PF0489791 Placebo 3 256 
T2DM, on RAS blockade. GFR: 
30–90 UACR: >300 
UACR 
Significant reduction in UACR (15.7%) 
compared to placebo  
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Table 2. Cont. 
Drug Comparator Months N Study Population Primary Endpoint Results 
CTP499 Placebo 12 177 
T2DM, on RAS blockade. GFR: 
23–89. UACR: 200–5000 if 
male 300–5000 if female 
UACR after 24 weeks 
Failed to meet the primary endpoint. Serum 
creatinine after 48 weeks lower (mean increase 
in CTP499; 0.13 mg/dL versus  
Placebo: 0.21 mg/dL, p = 0.057) 
Bardoxolone  
RTA-402 
Placebo (vs. 3 doses 
of the drug) 
12 227 
T2DM, on RAS blockade. GFR: 
20–45 
GFR at 24 weeks 
Significant increases in GFR, as compared 
with placebo (low dose group: +8. Medium 
dose: +11. High dose: +10 (p < 0.001). 
CCX 140-B Placebo 13 332 
T2DM, on RAS blockade. GFR: 
>25 UACR: 100–3000 
UACR 
Decreased albuminuria by 24% and after an 
initial reduction in eGFR, decreased the slope 
of eGFR loss 
Pirfenidone 
Placebo (vs. 2 doses 
of the drug) 
12 77 
DMT1 and T2DM, not 
specifically on RAS blockade. 
GFR: 20–75 
GFR after 1 year 
Mean GFR increased in pirfenidone +3.3 
whereas decreased in placebo −2.2  
(p = 0.026) 
LY2382770  
Anti-TGF-β1 mAb Placebo 12 416 
DMT1 and T2DM, on  
RAS blockade. GFR:  
PCR > or equal 800 
Serum creatinine Terminate: futility 
Pyridoxamine 
Placebo (vs. 2 doses 
of the drug) 
12 317 
T2DM, on RAS blockade. sCr 
1.3–3.3 female or 1.5–3.5 male. 
PCR > 1200 
Serum creatinine 
Failed to meet primary endpoint. Subgroup 
analysis: in the lowest tertile of baseline sCr, 
Pyridorin associated with a lower average 
change in serum creatinine concentration at 52 
weeks (drug 1: −0.28 drug 2: 0.07 placebo: 
0.14 (p = 0.05) 
T2DM: type 2 diabetes mellitus; eGFR: estimated glomerular filtration rate in mL/min/1.73 m2; sCr: serum creatinine in mg/dL; UACR: urinary albumin-to-creatinine 
ratio in mg/g; P24h: proteinuria g/24 h; PCR: protein/creatinine ratio in mg/g; mAb, monoclonal antibody. 
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2. Current Therapy for Diabetic Kidney Disease 
DKD is characterized by increasing albuminuria that progresses from A1 category of the 2012 KDIGO 
classification of CKD (urinary albumin/creatinine ratio (UACR) 30–300 mg/g) to A2 (UACR 300 
mg/g) and is followed by a gradual decrease in glomerular filtration rate (GFR), leading to  
end-stage renal disease (ESRD) [9]. Residual albuminuria after initiation of RAS blockade is the main 
risk factor for progression of DKD. However, GFR may be reduced in the absence of significant 
albuminuria in type 2 DM (T2DM) [10,12,13]. Non-proteinuric DKD usually progresses more slowly. 
Hyperuricemia and systemic inflammation are risk factors for progression. Direct induction of tubular 
cell stress by high glucose levels and glucose degradation products may elicit pro-inflammatory and 
fibrogenic response even when albuminuria is low [14,15]. ACE inhibitors or ARBs control blood 
pressure, reduce proteinuria and slow the loss of renal function in patients with DKD and  
UACR >30 mg/g [3] or hypertension and normoalbuminuria [16]. Dual RAS blockade (ACE inhibitor 
plus ARB) is not recommended by Kidney Disease Outcome Quality Initiative. (KDOQI), Kidney 
Disease Improving Global Outcomes (KDIGO) or American Diabetes Association (ADA) guidelines 
as no additional efficacy in terms of renal function has been demonstrated and the incidence and 
severity of adverse effects is increased [3,17–19]. However, some experts disagree with this 
recommendation [20,21]. 
The number of promising drugs that failed at the clinical trial stage in the field of DKD is ever 
increasing. Most clinical trials had as primary outcomes albuminuria or eGFR, and the interventional 
drug was usually added to RAS blockade. Either lack of efficacy or safety concerns were the reasons 
for failure. Bardoxolone methyl, inhibitors of protein kinase C (ruboxistaurin) or of AGEs formation 
(pimagedine/aminoguanidine, pyridoxamine), and sulodexide, have failed to find a place in the 
treatment of DKD [7,22]. Pirfenidone, anti-connective tissue growth factor (CTGF) or, anti-TGF-β 
monoclonal antibodies, and antifibrotic therapies are no longer being pursued in patients with DKD [7]. 
The early termination of a phase 2 clinical trial of the neutralizing anti-TGF-β1 antibody LY2382770 
due of futility to preserve renal function in DKD was announced at the 2014 American Society of 
Nephrology meeting [23]. Pyridoxamine is still being pursued in an ongoing phase 3 trial based on 
post-hoc analysis of phase 2 data that suggested a non-dose-dependent benefit in serum creatinine with 
marginal statistical significance [23,24]. 
3. Ongoing Clinical Trials 
Currently ongoing randomized controlled trials in DKD are further exploring tested concepts (as an 
example, endothelin receptor antagonism with improved molecules or vitamin D receptor activation), 
old drugs (e.g., allopurinol) or novel therapeutic approaches (e.g., targeting fibrosis or inflammation). 
Inflammation is considered a key contributor to progression of DKD and positive results were recently 
reported for anti-inflammatory agents in clinical trials [25]. Of ongoing trials, only the phase 3 
atrasentan RCT may result in a new therapeutic indication, while most other trials will provide  
proof-of-concept. Most clinical trials of nephroprotective agents in DKD use albuminuria as the 
primary outcome because this design enables a shorter follow-up duration and smaller sample  
size [26–31]. However, these are usually phase 2 data that require demonstration in phase 3 studies 
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that GFR is also preserved. In these regard, trials assessing GFR and specially measured GFR are more 
relevant. Recently, a 30% reduction in eGFR over two years was reported to be a more frequent 
outcome than doubling of serum creatinine and to be strongly associated with the risk of ESRD [32]. 
Thus, this endpoint may be considered as an end point for CKD progression, especially for drugs with 
no hemodynamic actions. 
3.1. Optimizing Already Tested Approaches or Drugs 
Some ongoing trials are exploring drugs targeting molecular mechanisms that have already been 
successfully targeted for kidney injury or other diseases. 
3.1.1. Vitamin D Receptor Activators 
Vitamin D receptor (VDR) activation has anti-inflammatory, immunologic and nephroprotective 
actions [33]. Activation of podocyte VDR protects from inflammation or fibrosis triggered by 
metabolic abnormalities [34,35]. Diabetic animals that lack VDR develop albuminuria, whilst VDR 
activation by paricalcitol (19-nor-1,25-(OH)2-vitamin D2) or calcitriol decreases proteinuria [33,34]. In 
small cohorts paricalcitol decreased proteinuria [36-38]. However, a phase 2 RCT (VITAL) exploring 
the antiproteinuric effect of 1 μg or 2 μg/24 h paricalcitol as add-on to RAS blockade in CKD stages 
2–4 DKD failed to meet the primary end-point (change in UACR at 24 weeks: group difference for 
paricalcitol versus placebo of −15%, p = 0.071) [26]. Post-hoc analysis disclosed that the higher dose 
decreased albuminuria in patients with high salt ingestion. The study was marred by the high 
prevalence of vitamin D deficiency that did not allow discrimination of therapeutic effects of 
paricalcitol from replacement of vitamin D [39] and was probably underpowered. The Antiproteinuric 
Effect of Selective Vitamin d Receptor Activation by Paricalcitol in Type 2 Diabetes Patients on Low 
or High Sodium Diet and Stable Ras Inhibitor Therapy (PROCEED) trial [23] is exploring the 
antialbuminuric effect of 2 μg/24 h paricalcitol or placebo for four months on top of RAS blockade in 
patients with T2DM and UACR >300 mg/24 h who have low or high salt intakes, in order to clarify 
the interaction between salt intake and VDR activators. 
3.1.2. Endothelin Receptor Antagonists 
Endothelins are small pleiotropic peptides that promote hypertension, albuminuria, insulin 
resistance, inflammation, fibrosis and endothelial dysfunction [27]. Endothelin-1 activates receptors 
ETA, ETB1 and ETB2 [27]. ETA activation is thought to have disease-causing effects, whereas ETBs 
are natriuretic [27, 40–42]. However, even very selective ETA blockers cause fluid retention. This side 
effect led to the termination of a phase 3 trial of avosentan in DKD, despite a significant reduction in 
albuminuria (44%–49% as compared with 10% for placebo) when added to RAS blockade [43]. 
Atrasentan is a more selective ETA antagonist than avosentan that in phase 2 trials reduced UACR 
by 35%–42% versus 11% for placebo in DKD. Unfortunately, atrasentan caused dose-dependent 
peripheral edema (18%–46% of patients) [27]. A larger phase 2 trial (RADAR) confirmed a reduction 
of albuminuria of 35%–38%, but found no differences in peripheral edema, although atrasentan 
patients gained more weight and hematocrit was lower, suggesting volume overload [44]. For this 
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reason the currently ongoing SONAR phase 3 trial has strict entry criteria that exclude patients at risk 
of fluid overload. This may be a major limitation to the wider use of the drug if it becomes 
commercially available. SONAR is assessing the effect of atrasentan versus placebo as add-on to RAS 
blockade in 4148 patients with T2DM, eGFR 25–75 mL/min/1.73 m2 and UACR 300–5000 mg/g [23]. 
The primary outcome is time to the first occurrence of a composite renal end point (doubling of sCr 
levels or development of ESRD). SONAR is expected to be completed by February 2017. 
3.1.3. Mineralocorticoid Receptor Antagonists 
Aldosterone secreted in response to RAS activation binds and activates the mineralocorticoid 
receptor to regulate sodium balance and to promote inflammation and fibrosis [45]. Mineralcorticoid 
receptor antagonists as add-on to RAS blockade decrease albuminuria in diabetic and non-diabetic 
kidney disease, but their effect on long-term renal function has not been explored and may increase the 
risk of hyperkalemia [21,46,47]. The PRIORITY clinical trial is investigating the efficacy of the  
non-expensive, first generation mineralocorticoid receptor antagonist spironolactone for prevention of 
albuminuria in T2DM patients with normoalbuminuria at high risk of progression based on urinary 
proteomics assessment [48, 49]. 
Completed phase 2 trials that have tested the effect on albuminuria of newer, selective, nonsteroidal 
mineralocorticoid receptor antagonist MT-3995 or finerenone (BAY 94-8862) reported to have lower 
risk of hyperkalemia on top of RAS blockade in DKD (eGFR 30–60 mL/min/1.73 m2 and albuminuria 
≥300 mg/g) [46,50]. An abstract reported that finerenone was safe and decreased UACR and blood 
pressure at three months [51] and the drug is expected to enter phase 3 development in 2015. 
3.1.4. Xanthine Oxidase Inhibitors 
High serum uric acid levels are associated with the development and progression of DKD [52] and 
an open label clinical trial suggested that allopurinol may provide nephroprotection [53]. Ongoing 
clinical trials are addressing nephroprotection by commercially available xanthine oxidase inhibitors 
allopurinol and febuxostat. PERL is a phase 3 trial assessing the impact of allopurinol on eGFR in 480 
patients with T1DM, albuminuria and CKD stage 1 to 3A [54]. Nephroprotection by febuxostat is 
addressed by the ongoing FEATHER trial, which has as primary endpoint eGFR in patients with stage 
3 CKD and hyperuricemia but is not limited to diabetics [55]. The phase 2 study UPWARD is 
assessing topiroxostat effects on albuminuria in diabetic patients with hyperuricemia or gout and will 
be completed in December 2016 [23]. 
3.1.5. Phosphodiesterase Inhibitors 
Pentoxifylline is an anti-inflammatory phosphodiesterase inhibitor, which is used primarily to treat 
peripheral vascular disease. A randomized controlled trial reported that adding low-dose pentoxifylline 
(400 mg daily) to dual RAS blockade (losartan plus enalapril) in 50 patients with T2DM resulted in a 
decrease in urinary protein excretion from 616 mg/day at baseline to 192 mg/day at 6 months (p = 
0.000) [56]. The Pentoxifylline for Renoprotection in Diabetic Nephropathy (PREDIAN) study was an 
independent, open-label, randomized controlled clinical trial that explored add-on pentoxifylline to 
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maximized RAS blockade on renal disease progression in T2DM patients with CKD stages 3–4. 
PREDIAN randomized 169 Caucasians patients (mean age 70 years, mean duration of DM 15 years) to 
a control group or a treatment group that received pentoxifylline (1200 mg/day). The mean baseline 
eGFR was 37 ± 12 mL/min/1.73 m2, 69% of patients had GFR category G3 and 91% had  
UACR >300 mg/g. All patients were hypertensive, most had hyperlipidemia, and more than 40% had 
medical history of coronary heart disease. After 24 months of follow-up, treatment with pentoxifylline 
was associated with a slower rate of eGFR loss: in control patients eGFR was 4.3 mL/min/1.73 m2 
lower than in pentoxifylline-treated patients. The difference in the reduction of eGFR between the 
groups reached statistical significance after one year, suggesting that a long-period of pentoxifylline 
treatment is necessary to achieve a protective effect on renal function. In addition, this study confirmed 
the additive antiproteinuric effect of pentoxifylline in T2DM with residual proteinuria, with a mean 
difference of 21% in favor or pentoxifylline respect to the control group, an effect that was significant 
from the sixth month [57]. 
CTP-499 incorporates deuterium at select positions of 1-((S)-5-hydroxyhexyl)-3,7-dimethylxanthine 
(HDX), an active metabolite of pentoxifylline, improving the metabolism profile [58]. Results from a phase 
2 trial reported in abstract form indicate that in 182 patients with T2DM DKD (UACR 300–5000 mg/g; 
eGFR 23–89 mL/min/1.73 m2) 600 mg PO BID CTP-499 failed to meet the primary endpoint (change 
in UACR after 24 weeks), but a promising effect on serum creatinine was observed after 48 weeks 
(mean increase in serum creatinine levels 0.13 mg/dL versus 0.21 mg/dL, p = 0.057). Furthermore, 
only 1.5% (1/65) of patients in the CTP-499 group experienced a ≥50% increase in sCr, versus 5/58 
(8.6%) of patients on placebo (p < 0.05). The rise in UACR was lower in patients receiving CTP-499 
(24 mg/g versus 222 mg/g on placebo, p = 0.13) [59]. The company announced in July 2014 that it 
would pursue phase 3 trials, but no new trials were posted at clinicaltrials.gov as of 1 April 2015. 
PF-00489791 is expected to have mainly hemodynamic actions by increasing the intracellular 
cGMP pool through inhibition of the cGMP hydrolyzing enzyme phosphodiesterase type 5. A recently 
completed 12-week phase 2 clinical trial in DKD reported in abstract form a significant reduction in 
UACR (16%) [60]. 
3.1.6. Serotonin Receptor Antagonists 
Sarpogrelate is a 5HT2A/5-HT2B receptor antagonist antiplatelet agent that is as effective as aspirin in 
preventing macrovascular complications of T2DM and is commercially available in several countries [61]. 
Sarpogrelate decreased type IV collagen production by cultured mesangial cells [62] reduced 
albuminuria is experimental DKD, [63] and decreased antibody-mediated glomerular injury [64] and 
nephrotoxin-induced kidney fibrosis, suggesting mechanisms of action beyond the effects on platelets [65]. 
The primary outcome of an ongoing phase 4 trial (SONATA) is UACR in T2DM. 
3.2. Novel Therapeutic Approaches 
Some trials are exploring or have recently explored novel therapeutic targets or drugs in DKD. 
  
J. Clin. Med. 2015, 4 1336 
 
 
3.2.1. Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators 
Bardoxolone methyl is a synthetic triterpenoid activator of the transcription factor Nrf2 and an 
inhibitor of nuclear factor κB (NFκB) [66]. In a promising phase 2 RCT bardoxolone methyl increased 
estimated GFR in DKD at the expense of higher blood pressure and albuminuria [29]. In addition, 
anorexia, weight loss and hypomagnesemia were noted. A phase 3 trial (BEACON) confirmed these 
actions and side effects, but was terminated for safety concerns related to heart failure probably as a 
consequence of fluid retention [67]. This was probably the end of the road for bardoxolone methyl in 
DKD. Signs of toxicity had already been reported in experimental CKD, although they were dismissed 
as a consequence of a defective batch of the drug [68]. Nevertheless, Nrf2 activators such as dimethyl 
fumarate are currently used to treat multiple sclerosis [69,70] and new trials are exploring the safety 
and tolerability of the bardoxolone methyl formulation RTA 402 [23]. Thus, Nrf2 activators for DKD 
may not be entirely dismissed. Either successful and safe use for another indication or observations of 
improved kidney outcomes in diabetic multiple sclerosis patients may trigger a second round of 
interest in bardoxolone methyl or other Nrf2 activators for DKD. Indeed, despite worldwide 
termination of bardoxolone methyl clinical research programs for DKD following the termination of 
the BEACON trial, a reanalysis of the potential risk/benefit of the drug for the Japanese population led 
to reinitiating RCTs for DKD in Japan in 2015. Since the incidence of cardiovascular events is lower 
in Japanese CKD patients with DM than in European or US patients, it was hypothesized that a  
dose-escalation study in this population may be devoid of the risks observed in BEACON; in which 
most of the severe adverse effects were concentrated within the first month of therapy. A  
placebo-controlled RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled 
Clinical Trial in Patients with Chronic Kidney Disease and Type 2 Diabetes, TSUBAKI, 
NCT02316821) is currently recruiting participants in Japan. The purpose is to assess the safety and 
efficacy (insulin clearance) of RTA 402 in 72 CKD patients with T2DM when administered once daily 
for 16 weeks in an intrapatient dose escalation design. The estimated study completion date is 
December 2017. Dose and inclusion criteria were not available at clincialtrials.gov. However, several 
issues remain unsolved: the rapid time-course of the increase in estimated GFR suggests a 
hemodynamic basis. If this was the case, then bardoxolone methyl actions would be the complete 
opposite to the current standard of therapy (RAS blockade): bardoxolone methyl appears to increase 
GFR, albuminuria and blood pressure through a hemodynamic effect, while RAS blockade decreases 
these three parameters and it is precisely the decrease of the three parameters that is thought to 
contribute to nephroprotection. As a consequence, if bardoxolone methyl were indeed successful at 
preventing CKD progression, the whole concept of nephroprotection in DKD would need to be rewritten. 
3.2.2. Chemokine Inhibitors 
High glucose elicits a pro-inflammatory response in tubular cells and podocytes characterized by 
chemokine secretion that promotes kidney inflammation [71]. An ongoing phase 2 trial is exploring the 
safety, tolerability and effect on albuminuria of the chemokine receptor BMS-813160. A phase 2 trial 
of CCR 2/5 antagonists PF-04634817 was recently completed but results are not yet available. Another 
recently completed phase 2 trial provided promising results for CCX140, an oral small molecule 
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inhibitor of CCR2. Targeting the chemokine MCP-1/CCL2 or its receptor CCR2 by different means 
(neutralizing antibodies, receptor antagonists, inhibitors, DNA vaccines, mutant genes or enantiomeric 
RNA oligonucleotides (L-RNA aptamer )) decreased albuminuria, kidney injury and inflammation and 
preserved kidney function in experimental kidney injury, including DKD [71–73]. CCX140 improved 
metabolic control in diabetic mice [74] and decreased albuminuria and podocyte injury and improved 
glycemic control in transgenic diabetic human CCR2 knockin mice [73]. A press report indicated that 
CCX140 improved the metabolic profile in human T2DM in phase 2 trials. Furthermore, over  
52 months, 5 mg/day CCX140 decreased albuminuria by 24% and after an initial reduction in  
eGFR, decreased the slope of eGFR loss [75]. While the data remain unpublished, phase 3 trials are  
being designed. 
3.2.3. Anti-IL-1β Antibodies 
Gevokizumab is a potent recombinant monoclonal antibody, with unique allosteric modulating 
properties [76]. It binds to human interleukin-1 beta (IL-1β), a pro-inflammatory cytokine, with high 
affinity resulting in inhibition of IL-1β signaling and pro-inflammatory activity [77]. Gevokizumab is 
currently being studied in multiple diseases, including global Phase 3 clinical programs in chronic 
inflammatory disease such as Behçet’s disease, uveitis, non-infectious uveitis, and pyoderma 
gangrenosum [78]. A dose-response study of gevokizumab in patients with T2DM and DKD with a 
primary outcome of measured GFR will start in 2015 [79]. 
3.2.4. NFκB Inhibitors 
NFκB is a key contributor to experimental kidney injury and there is evidence for NFκB activation 
in human DKD [80]. Bindarit (2-((1-benzyl-indazol-3-yl) methoxy)-2-methyl propionic acid) 
downregulates the activation of specific NFκB dimers, reducing chemokine expression [81]. In lupus 
nephritis phase 2 trials, bindarit for 24 weeks reduced albuminuria and urinary CCL2 excretion [82]. A 
small phase 2 trial in 100 patients with DKD (NCT 01109212) reported that bindarit administration for 
12 weeks reduced albuminuria, [83] but the full results have not been published and no new trials of 
this agent are ongoing. 
3.2.5. Jakinibs 
Jakinibs are small molecule inhibitors of Janus kinases (JAK) activation. JAKs activate the family 
of transcription factors of Signal Transducer and Activator of Transcription (STAT) which are thought 
to promote hyperglycemia-induced kidney injury. Dysregulation of the JAK-STAT pathway has been 
documented in human progressive DKD [84]. Inhibitors of JAK2 (AG-490) which might have 
additional cytoprotective effects such as activation of hypoxia inducible factor 1 (HIF-1) [85,86]. 
JAK3 (Janex-1) and STAT1 (fludarabine) have been proposed as anti-diabetic agents [87,88]. 
Overexpression of suppressors of cytokine signaling (SOCS)-1 and SOCS-3, the intracellular negative 
regulators of JAK-STAT signaling is also protective in experimental DKD [89]. The oral JAK1 and 
JAK2 inhibitor baricitinib (formerly LY3009104, INCB28050), which is in phase 3 development for 
rheumatoid arthritis, [90] might also have renoprotective effects. A recently completed phase 2 trial 
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tested baricitinib or placebo as add-on to RAS blockade in 129 patients with DKD and UACR  
300–5000 mg/g. The primary outcome is change from baseline UACR at 24 weeks of treatment. Study 
results are still pending publication [23]. 
3.2.6. Antioxidants 
Oxidative stress is a contributor to tissue injury in DKD and other diseases, but has proved elusive 
as a therapeutic target. GKT137831 is a NOX1/4 inhibitor undergoing a phase 2 trial that was 
completed in February 2015, but results are not available yet [23]. 
3.2.7. Galectin-3 Antagonist 
Galectin-3 is a lectin that regulates cell proliferation, apoptosis, cell adhesion and affinity for advanced 
glycation end products and is upregulated in experimental and human DKD and ESRD [91-95]. In diabetic 
patients, glomerular galectin-3-positive cells correlated with decreasing renal function [96]. In human 
cohorts, galectin-3 levels increased with progressive renal impairment and were independently 
associated with all-cause death [97]. A clinical trial is exploring the effect of the galectin-3 antagonist 
GCS-100 for 26 weeks on eGFR in DKD [23]. However, some data point to a requirement of  
galectin-3 for nephroprotection. Thus, galectin-3 knock-out mice develop more severe DKD as well as 
spontaneous age-dependent glomerular lesions [98,99]. 
3.2.8. Integrin Blocker 
VPI-2690B is an antibody against the αVß3 integrin receptor (vitronectin receptor) that is currently 
undergoing phase 2 RCTs in DKD with decrease of albuminuria as primary outcome [23]. αVβ3 
allows interaction of the podocyte with matrix proteins [100]. Expression of αVβ3 receptor and its 
ligand vitronectrin is increased in experimental DKD [101]. αVβ3 integrin receptor activation is 
thought to contribute to podocyte injury when activated by soluble urokinase plasminogen activator 
receptor (suPAR) in the presence of low podocyte-specific acid sphingomyelinase-like 
phosphodiesterase 3b (SMPDL3b) levels. However, in DKD both serum suPAR and glomerular 
SMPDL3b expression are increased. Under these conditions, SMPDL3bwas reported to prevent αVβ3 
integrin activation by suPAR and this resulted in podocyte cell death in cultured cells [102]. While the 
pathogenicity of suPAR in DKD in debated, these observations raise concerns over the safety of  
VPI-2690B, since by preventing αVβ3 in a high suPAR context it may favor podocyte death. However, 
VPI-2690B was observed to decrease proteinuria, diminish glomerular basement membrane thickening 
and podocyte foot process effacement in experimental DKD in pigs [103]. 
3.2.9. Apoptosis Signal-Regulating Kinase 1 (ASK1, Mitogen-Activated Protein Kinase Kinase Kinase 
5, MAP3K5) Inhibitors 
ASK-1 is a member of the MAP kinase kinase kinase superfamily that activates c-Jun N-terminal 
kinase (JNK) and p38MAPK in a Raf-independent fashion in response to oxidative stress and inhibited 
by the endogenous molecule thioredoxin [104,105]. ASK-1 targeting protected from diabetes-induced 
endothelial dysfunction, endothelial cell senescence and endoplasmic reticulum stress in experimental 
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DKD or cultured cells [104,106,107]. ASK1 may also be diabetogenic [108]. The ASK1 inhibitor GS-4997 
is undergoing RCT in DKD with albuminuria and estimated GFR as primary outcome [23]. 
4. Conclusions 
Treatment of DKD still relies on RAS targeting drugs, which were first observed to reduce 
albuminuria over 30 years ago. The lack of advances in this area is worrisome, given the increase in 
global premature mortality from CKD and DKD in recent decades. While adequate blood pressure 
control, low salt diet and adequately dosed single RAS blockade may slow or stabilize the rate of 
progression of DKD in some patients, DKD still remains the most frequent cause of ESRD. Despite 
several setbacks, the field of clinical trials for add-on therapies for DKD on top of RAS blockade is 
currently active. Recent success with pentoxifylline on renal function preservation, positive 
preliminary data with chemokine targeting drugs and successful phase 2 trials with endothelin receptor 
antagonists point towards inflammation as the common denominator underlying promising therapeutic 
approaches. Ongoing phase 3 trials with atrasentan and soon to start trials with gevokizumab provide 
the basis for cautious optimism for the future. 
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